Loading...
•
Jun 30, 2023
CRISPR Therapeutics Q2 2023 Earnings Report
CRISPR Therapeutics reported financial results and business updates for Q2 2023.
Key Takeaways
CRISPR Therapeutics reported a net loss of $77.7 million for the second quarter of 2023, with total collaboration revenue of $70.0 million. The FDA accepted BLAs for exa-cel for severe SCD and TDT, marking significant progress towards delivering innovative gene-edited therapies.
FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT).
Enrollment and dosing are ongoing for CTX110 targeting CD19+ B-cell malignancies and CTX130 targeting CD70 for the treatment of T cell lymphomas.
Enrollment is ongoing and dosing initiated for next-generation CAR T candidates, CTX112 targeting CD19+ B-cell malignancies and CTX131 targeting CD70+ solid tumors.
A Phase 1/2 clinical trial of VCTX211 for the treatment of Type 1 Diabetes (T1D) continues with enrollment and dosing ongoing.
Forward Guidance
CRISPR Therapeutics is advancing multiple clinical programs and expects to initiate a clinical trial for CTX310 this year, with plans to enter the clinic with an investigational program targeting lipoprotein (a) (Lp(a)) in the first half of 2024.
Positive Outlook
- Advancing lead in vivo program, CTX310, targeting ANGPTL3, into the clinic this year.
- Progressing an investigational program targeting lipoprotein (a) (Lp(a)) and expects to enter the clinic in the first half of 2024.
- Continuing enrollment and dosing in a Phase 2 single-arm potentially registrational clinical trial of CTX110.
- Continuing enrollment and dosing in the Phase 1 COBALT-LYM trial evaluating the safety and efficacy of CTX130.
- Continuing to enroll and has initiated dosing in a Phase 1 clinical trial of CTX112.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...